5:02 PM
 | 
Feb 06, 2009
 |  BC Extra  |  Company News

EC approves Nplate

The European Commission approved an MAA from Amgen (NASDAQ:AMGN) for Nplate romiplostim to treat chronic idiopathic thrombocytopenia purpura (ITP) in splenectomised adults who are refractory...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >